...
首页> 外文期刊>PDA journal of pharmaceutical science and technology >Design, development, and optimization of orally disintegrating tablets of etoricoxib using vacuum-drying approach.
【24h】

Design, development, and optimization of orally disintegrating tablets of etoricoxib using vacuum-drying approach.

机译:使用真空干燥方法设计,开发和优化依托考昔口服崩解片。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Etoricoxib is a cyclooxygenase 2 (COX-2) inhibitor that selectively inhibits the COX-2 enzyme and decreases the incidences of side effects associated with these agents. It is commonly prescribed for acute pain, gouty arthritis, and rheumatoid arthritis. Conventional tablets of etoricoxib are not capable of rapid action, which is required for faster drug effect onset and immediate relief from pain. Thus, the aim of the present investigation is to formulate orally disintegrating tablets (ODTs) of etoricoxib. A combination of the superdisintegrants with a sublimation technique was used to prepare the tablets. Tablets were prepared using a direct compression method employing superdisintegrants such as low substituted hydroxylpropyl methyl cellulose (L-HPMC), low substituted hydroxyl-propyl cellulose (L-HPC), crospovidone, croscarmellose sodium, and sodium starch glycolate. Tablets of etoricoxib prepared using L-HPC exhibited the least friability and disintegration time (approximately 65 s). To decrease thedisintegration time further, a sublimation technique was used along with the superdisintegrants for the preparation of ODTs. The use of sublimating agents including camphor, menthol, and thymol was explored. The addition of camphor lowered the disintegration time (approximately 30 s) further, but the percent friability was increased. A 3(2) full factorial design was employed to study the joint influence of the amount of superdisintegrant (L-HPC) and the amount of sublimating agent (camphor) on the percent of friability and the disintegration time. The results of multiple linear regression analysis revealed that for obtaining an effective ODT of etoricoxib, higher percentages of L-HPC and camphor should be used. Checkpoint batches were prepared to validate the evolved mathematical model. A response surface plot is also presented to graphically represent the effect of the independent variables on the percent of friability and the disintegration time. The approach using the optimization technique helped to produce a detailed understanding of the effects of formulation parameters.
机译:Etoricoxib是一种环氧合酶2(COX-2)抑制剂,可选择性抑制COX-2酶并降低与这些药物相关的副作用的发生率。通常用于急性疼痛,痛风性关节炎和类风湿关节炎。常规的依托考昔片不能快速起作用,这对于更快的起效和立即缓解疼痛是必需的。因此,本研究的目的是配制依托昔布的口腔崩解片(ODT)。将超崩解剂与升华技术结合使用以制备片剂。使用直接崩解剂,例如低取代的羟丙基甲基纤维素(L-HPMC),低取代的羟丙基纤维素(L-HPC),交聚维酮,交联羧甲基纤维素钠和羟乙酸淀粉钠,直接压片法制备片剂。使用L-HPC制备的依托考昔片显示出最小的脆碎度和崩解时间(约65 s)。为了进一步减少崩解时间,将升华技术与超崩解剂一起用于制备ODT。探索了包括樟脑,薄荷醇和百里酚在内的升华剂的使用。樟脑的添加进一步缩短了崩解时间(约30 s),但脆碎百分率提高了。采用3(2)全因子设计研究了超级崩解剂(L-HPC)量和升华剂(樟脑油)量对脆性百分比和崩解时间的联合影响。多元线性回归分析的结果表明,为了获得有效的依托昔布ODT,应使用更高百分比的L-HPC和樟脑。准备了检查点批次以验证演化的数学模型。还提供了一个响应面图,以图形方式表示自变量对脆性百分比和崩解时间的影响。使用优化技术的方法有助于对配方参数的效果产生详细的了解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号